Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Trinity Biotech ( (TRIB) ) has provided an update.
On January 29, 2025, Trinity Biotech announced its monitoring of a U.S. Executive Order potentially impacting sales of its rapid HIV tests due to a pause in new funding obligations for foreign assistance programs. Additionally, the company disclosed that its U.S. subsidiaries received and had forgiven loans under the Paycheck Protection Program in 2021, but eligibility issues raised by the Department of Justice in 2024 could require returning the funds.
More about Trinity Biotech
Trinity Biotech is a commercial-stage biotechnology company based in Ireland, focusing on human diagnostics and diabetes management solutions, including wearable biosensors.
YTD Price Performance: 43.16%
Average Trading Volume: 2,125,022
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $15.46M
For a thorough assessment of TRIB stock, go to TipRanks’ Stock Analysis page.
